CANADIAN NEUROLOGICAL SCIENCES FEDERATION
FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

A New Era of Medicine, Now & the Future

Gene Therapy for Paediatric Neuromuscular Diseases

Join us for this innovative virtual CNSF 2021 symposium that will review current and emerging gene therapy research for the treatment of paediatric neuromuscular diseases.

December 2, 2021 | **7:00 PM (EST)**

Through expert presentations, participants will learn about exciting advances in gene therapy for the treatment of neuromuscular diseases, including SMA. Speakers will also explore the critical role newborn screening plays in facilitating pre-symptomatic diagnosis and early treatment of disease, and the implementation of newborn screening in Canada. The session will then be followed by an interactive live Question & Answer session with all speakers.

CLICK HERE TO REGISTER

EVENT SPEAKERS:

Jim Dowling
MD, PhD, FRCPC
SickKids Hospital

Hugh McMillan
MD, MSc, FRCPC, FAAN
Montreal Children's Hospital

Pranesh Chakraborty
MD, FRCPC, FCCMG
Children's Hospital
of Eastern Ontario

Stacey Lintern
CEO
Muscular Dystrophy Canada

Homira Osman, PhD
VP
Research and Public Policy
Muscular Dystrophy Canada

PROGRAM OBJECTIVES:

Upon completion of this program, participants will be better able to:

- Discuss the current clinical research evidence and application of gene therapy in paediatric neurological and neuromuscular diseases (NMD)
- Appraise the role of current treatments in helping SMA patients reach their milestones
- Summarize the key considerations, learnings and outcomes related to public and private sectors working on newborn screening (NBS)
- Determine the role of the clinical and research community in facilitating the inclusion of additional NMDs' into NBS

CLICK HERE TO REGISTER

For any questions about the event, contact mhtherrien@medplan.ca.

This Webinar is an unaccredited group learning approved by the Canadian Neurological Sciences Federation.
The program was developed by the Canadian Neurological Sciences Federation and Faculty and was planned to achieve scientific integrity, objectivity and balance.

This learning activity is made possible with support from Novartis Pharmaceuticals Canada Inc.